Compass Therapeutics Investor Presentation Deck

CTX-009: BTC Patient Demographics and Current Treatments Incident Cases 1L Treatment Doublet chemo of gemcitabine + cisplatin (ABC-02 study) Or Gemcitabine/cisplatin + durvalumab (recently approved for 1L) US 18,400¹ FOLFOX 5% ORR 0.9 Mos OS A EU5 21,800² 1. NCI Surveillance, Epidemiology, and End Results (SEER) program 2. Delveinsight/company estimates COMPASS THERAPEUTICS 3. International Agency for Research on Cancer/GLOBOCAN Japan Worldwide 14,329² >200,000³ 2L Treatment FGFR2 mutation Pemigatinib (10-15% of CCA) IDH1 mutation Ivosidenib (1-3% of BTC) MSI-H tumors PD-1 Inhibitor (<1% of BTC) Clinical trial 25

View entire presentation